Title: Identification of potent Yes1 kinase inhibitors using a library screening approach.
Journal: Bioorganic & medicinal chemistry letters 20130801
Title: Phase I study of RO4929097, a gamma secretase inhibitor of Notch signaling, in patients with refractory metastatic or locally advanced solid tumors.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20120701
Title: Initial testing (stage 1) by the pediatric preclinical testing program of RO4929097, a γ-secretase inhibitor targeting notch signaling.
Journal: Pediatric blood & cancer 20120501
Title: A phase II study of RO4929097 in metastatic colorectal cancer.
Journal: European journal of cancer (Oxford, England : 1990) 20120501
Title: High tumor levels of IL6 and IL8 abrogate preclinical efficacy of the γ-secretase inhibitor, RO4929097.
Journal: Molecular oncology 20110601
Title: Validation and implementation of a liquid chromatography/tandem mass spectrometry assay for quantitation of the total and unbound RO4929097, a γ-secretase inhibitor targeting Notch signaling, in human plasma.
Journal: Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20110601
Title: The novel gamma secretase inhibitor RO4929097 reduces the tumor initiating potential of melanoma.
Journal: PloS one 20110101
Title: Preclinical profile of a potent gamma-secretase inhibitor targeting notch signaling with in vivo efficacy and pharmacodynamic properties.
Journal: Cancer research 20091001
Title: Luistro L, et al. Preclinical profile of a potent gamma-secretase inhibitor targeting notch signaling with in vivo efficacy and pharmacodynamic properties. Cancer Res. 2009, 69(19), 7672-7680.
Title: Debeb BG, et al. Pre-clinical studies of Notch signaling inhibitor RO4929097 in inflammatory breast cancer cells. Breast Cancer Res Treat. 2012.
Title: Huynh C, et al. The novel gamma secretase inhibitor RO4929097 reduces the tumor initiating potential of melanoma. PLoS One. 2011, 6(9), e25264.
